VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

PHR.US

25.33

-0.94%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

PHR.US

25.33

-0.94%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

PHR.US

25.33

-0.94%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

PHR.US

25.33

-0.94%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

PHR.US

25.33

-0.94%↓

Search

Medtronic PLC

Închisă

SectorSănătate

88.44 -1.53

Rezumat

Modificarea prețului

24h

Curent

Minim

88.2

Maxim

89.76

Indicatori cheie

By Trading Economics

Venit

32M

1.3B

Vânzări

-111M

8.3B

P/E

Medie Sector

27.479

73.239

EPS

1.39

Randament dividend

3.11

Marjă de profit

15.798

Angajați

95,000

EBITDA

-40M

2.4B

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+7.28% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

3.11%

3.06%

Următoarele câștiguri

22 mai 2025

Data viitoare de dividende

11 apr. 2025

Următoarea dată ex-dividende

27 iun. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-5B

116B

Deschiderea anterioară

89.97

Închiderea anterioară

88.44

Sentimentul știrilor

By Acuity

36%

64%

109 / 386 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Weak Bullish Evidence

Medtronic PLC Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

18 feb. 2025, 12:24 UTC

Câștiguri

Medtronic 3Q Revenue Rises on Strength in Cardiovascular, Neuroscience

19 nov. 2024, 12:27 UTC

Câștiguri

Medtronic Narrows Fiscal Year Guidance as 2Q Tops Views

27 feb. 2025, 10:30 UTC

Top știri

Squeezed by Strong Dollar, Companies Try to Neutralize Currency Swings -- WSJ

18 feb. 2025, 11:47 UTC

Câștiguri

Medtronic: Will Accelerate Top-, Bottom-Line Growth in 4Q >MDT

18 feb. 2025, 11:46 UTC

Câștiguri

Medtronic Still Sees FY25 Organic Revenue Growth 4.75%-5% >MDT

18 feb. 2025, 11:45 UTC

Câștiguri

Medtronic 3Q Adj EPS $1.39 >MDT

18 feb. 2025, 11:45 UTC

Câștiguri

Medtronic 3Q Neuroscience Portfolio Rev $2.46B >MDT

18 feb. 2025, 11:45 UTC

Câștiguri

Medtronic 3Q Net $1.29B >MDT

18 feb. 2025, 11:45 UTC

Câștiguri

Medtronic 3Q Diabetes Rev $694M >MDT

18 feb. 2025, 11:45 UTC

Câștiguri

Medtronic 3Q Medical Surgical Portfolio Rev $2.07B >MDT

18 feb. 2025, 11:45 UTC

Câștiguri

Medtronic 3Q Cardiovascular Portfolio Rev $3.04B >MDT

18 feb. 2025, 11:45 UTC

Câștiguri

Medtronic 3Q Organic Revenue Up 4.1% >MDT

18 feb. 2025, 11:45 UTC

Câștiguri

Medtronic 3Q EPS $1.01 >MDT

18 feb. 2025, 11:45 UTC

Câștiguri

Medtronic Sees FY Adj EPS $5.44-Adj EPS $5.50 >MDT

18 feb. 2025, 11:45 UTC

Câștiguri

Medtronic 3Q Sales $8.29B >MDT

18 feb. 2025, 10:01 UTC

Câștiguri
Acțiuni populare

Stocks to Watch Tuesday: Intel, Baidu, Constellation Brands -- WSJ

21 ian. 2025, 19:15 UTC

Top știri

Medtronic Hires CFO From Renault -- Update

21 ian. 2025, 12:17 UTC

Top știri

Medtronic Hires CFO From Renault

19 nov. 2024, 12:12 UTC

Câștiguri

Medtronic Narrows FY Guidance as 2Q Tops Views

19 nov. 2024, 11:46 UTC

Câștiguri

Medtronic Sees High-Single-Digit Adjusted EPS Growth in 2nd Half of FY25 >MDT

19 nov. 2024, 11:46 UTC

Câștiguri

Medtronic Narrows FY25 Organic Rev Growth View to 4.75%-5% From 4.5%-5% >MDT

19 nov. 2024, 11:45 UTC

Câștiguri

Medtronic 2Q Medical Surgical Portfolio Rev $2.13B >MDT

19 nov. 2024, 11:45 UTC

Câștiguri

Medtronic 2Q Adj EPS $1.26 >MDT

19 nov. 2024, 11:45 UTC

Câștiguri

Medtronic 2Q Diabetes Rev $686M >MDT

19 nov. 2024, 11:45 UTC

Câștiguri

Medtronic 2Q Neuroscience Portfolio Rev $2.45B >MDT

19 nov. 2024, 11:45 UTC

Câștiguri

Medtronic 2Q Net $1.27B >MDT

19 nov. 2024, 11:45 UTC

Câștiguri

Medtronic 2Q Organic Revenue Up 5.0% >MDT

19 nov. 2024, 11:45 UTC

Câștiguri

Medtronic 2Q Cardiovascular Portfolio Rev $3.1B >MDT

19 nov. 2024, 11:45 UTC

Câștiguri

Medtronic Sees FY Adj EPS $5.44-Adj EPS $5.50 >MDT

19 nov. 2024, 11:45 UTC

Câștiguri

Medtronic 2Q Sales $8.4B >MDT

Comparație

Modificare preț

Medtronic PLC Așteptări

Obiectiv de preț

By TipRanks

7.28% sus

Prognoză pe 12 luni

Medie 96.4 USD  7.28%

Maxim 109 USD

Minim 85 USD

În baza a 19 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruMedtronic PLC - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

19 ratings

9

Cumpărare

9

Păstrare

1

Vânzare

Scor tehnic

By Trading Central

88.02 / 90.29Suport & Rezistență

Termen scurt

Weak Bullish Evidence

Termen mediu

Bullish Evidence

Termen lung

Weak Bullish Evidence

Sentiment

By Acuity

109 / 386 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Medtronic PLC

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists; and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat other non-exclusive diseases and conditions; and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems, and InPen, a smart insulin pen system. The company was founded in 1949 and is headquartered in Galway, Ireland.